查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1511811

美國血紅蛋白病市場規模、佔有率和趨勢分析報告：按類型、診斷、治療、地區和細分市場預測，2024-2030 年

U.S. Hemoglobinopathies Market Size, Share & Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease), By Diagnosis (Thalassemia, Sickle Cell Disease), By Therapy, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

美國血紅蛋白病市場的成長與趨勢：

Grand View Research, Inc.的最新報告顯示，到2030年，美國血紅素病市場規模預計將達到68.5億美元，2024年至2030年複合年成長率為12.5%。

鐮狀細胞疾病和地中海貧血等血紅素病患疾病率的上升是一個關鍵的市場促進因素。基因檢測和產前篩檢等診斷技術的進步改善了血紅蛋白疾病的早期檢測。此外，基因療法和CRISPR-Cas9等基因編輯技術等新治療方案的研究正在取得進展，未來有望獲得更有效的治療方法。

政府不斷採取措施提高對血紅蛋白血症的認知並改善受影響個人獲得護理的機會，這在推動市場方面發揮關鍵作用。研究和開發資金也在加速這一領域的創新。

製藥公司、研究機構和醫療保健提供者之間的合作將加速新治療方法的開發並改善患者護理。利用各公司優勢的合作關係可以加速藥物開發並改善治療結果。

美國血紅素病市場報告亮點

  • 到 2023 年，鐮狀細胞疾病在該類型細分市場中佔據主導地位，佔 60.1%，預計在預測期內將以最快的複合年成長率成長。這一成長的推動因素是生物製藥公司和非營利組織為改善鐮狀細胞疾病 (SCD) 治療的可及性而採取的越來越多的舉措。
  • 到2023年，鐮狀細胞疾病診斷領域將佔據最大市場。包括次世代定序和分子診斷等基因檢測方法的進步正在推動這一領域的成長。
  • 到 2023 年，鐮狀細胞疾病治療領域將佔據最大市場。市場成長是由越來越多的創新治療方法獲得核准所推動的，例如基因療法和旨在糾正遺傳異常的標靶治療。
  • 2022年4月，基因組醫學公司Sangamo Therapeutics宣布將其SAR445136鐮狀細胞疾病計畫從賽諾菲轉移至Sangamo。這一轉變代表了鐮狀細胞疾病基因編輯治療開發的重要一步。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章美國血紅素病市場變數、趨勢、範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 美國血紅素病市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國血紅蛋白病市場：類型估計和趨勢分析

  • 2023年及2030年市場佔有率
  • 細分儀表板
  • 按類型分類的市場前景
  • 2018-2030年市場規模及預測及趨勢分析

第5章美國血紅素疾病市場：診斷估計與趨勢分析

  • 2023年及2030年市場佔有率
  • 細分儀表板
  • 診斷市場前景
  • 2018-2030年市場規模及預測及趨勢分析

第6章美國血紅素病市場：治療估計與趨勢分析

  • 2023年及2030年市場佔有率
  • 細分儀表板
  • 不同療法的市場前景
  • 2018-2030年市場規模及預測及趨勢分析

第7章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
  • 公司簡介
    • Sangamo Therapeutics, Inc.
    • Global Blood Therapeutics, Inc.
    • bluebird bio, Inc.
    • Emmaus Life Sciences Inc.
    • Pfizer, Inc.
    • Novartis AG
    • Prolong Pharmaceuticals, LLC
    • Bioverativ Inc.
    • Celgene Corp.
Product Code: GVR-4-68040-295-9

U.S. Hemoglobinopathies Market Growth & Trends:

The U.S. hemoglobinopathies market size is anticipated to reach USD 6.85 billion by 2030, growing at a CAGR of 12.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of hemoglobinopathies, such as sickle cell disease and thalassemia, is a significant market driver. Advances in diagnostic techniques, such as genetic testing and prenatal screening, have improved the early detection of hemoglobinopathies. In addition, ongoing research into novel treatment options, including gene therapy and gene editing technologies like CRISPR-Cas9, holds promise for more effective therapies in the future.

The growing government initiatives to raise awareness about hemoglobinopathies and improved access to care for affected individuals play a crucial role in driving the market. Funding support for research and development efforts also accelerates innovation in this field.

Collaboration between pharmaceutical companies, research institutions, and healthcare providers fosters the development of new therapies and enhances patient care. Partnerships that leverage companies' strengths can accelerate drug development and improve treatment outcomes.

U.S. Hemoglobinopathies Market Report Highlights:

  • Sickle cell disease type dominated the type segment with 60.1% share in 2023 and is expected to grow at fastest CAGR over the forecast period. The growth is attributed to the increasing Initiatives of Biopharmaceutical Companies and Nonprofit Organizations Driving Improved Access to Sickle Cell Disease (SCD) Treatment.
  • The sickle cell disease diagnosis segment held the largest market in 2023. Advancements including genetic testing methods such as next-generation sequencing and molecular diagnostics are propelling the segment growth.
  • The sickle cell disease therapy segment held the largest market in 2023. The growing approval of innovative therapies, such as gene therapies and targeted treatments, designed to modify genetic abnormalities are propelling market growth.
  • In April 2022, Sangamo Therapeutics, a genomic medicines company, announced the transition of its SAR445136 sickle cell disease program from Sanofi to Sangamo. This transition marks a significant step in the development of a gene-edited therapy for sickle cell disease.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Diagnosis
    • 1.2.3. Therapy
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Diagnosis outlook
    • 2.2.3. Therapy outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Hemoglobinopathies Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Hemoglobinopathies Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Hemoglobinopathies Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Hemoglobinopathies Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 4.4.1. Thalassemia
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Sickle cell disease
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Other Hb variants
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Hemoglobinopathies Market: Diagnosis Estimates & Trend Analysis

  • 5.1. Diagnosis Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Hemoglobinopathies Market by Diagnosis Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 5.4.1. Thalassemia
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2. Alpha
      • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.2. Blood test
      • 5.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.3. Genetic test
      • 5.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.4. Prenatal genetic test
      • 5.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.5. Pre-implantation genetic test
      • 5.4.1.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.6. Electrophoresis
      • 5.4.1.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2.7. Others
      • 5.4.1.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3. Beta
      • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.2. Blood test
      • 5.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.3. Genetic test
      • 5.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.4. Prenatal genetic test
      • 5.4.1.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.5. Pre-implantation genetic test
      • 5.4.1.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.6. Electrophoresis
      • 5.4.1.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3.7. Others
      • 5.4.1.3.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Sickle cell disease
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2. Blood test
      • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.3. Genetic test
      • 5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.4. Prenatal genetic test
      • 5.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.5. Electrophoresis
      • 5.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.6. Others
      • 5.4.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Hb variants
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.3.2. Blood test
      • 5.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.3.3. Genetic test
      • 5.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.3.4. Prenatal genetic test
      • 5.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.3.5. Electrophoresis
      • 5.4.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.3.6. Others
      • 5.4.3.7. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Hemoglobinopathies Market: Therapy Estimates & Trend Analysis

  • 6.1. Therapy Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Hemoglobinopathies Market by Therapy Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 6.4.1. Thalassemia
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030, (USD million)
      • 6.4.1.2. Alpha
      • 6.4.1.2.1. Market estimates and forecasts 2018 to 2030, (USD million)
      • 6.4.1.2.2. Blood transfusion
      • 6.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.2.2.2. Iron chelation therapy
      • 6.4.1.2.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.2.3. Bone marrow transplant
      • 6.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.2.4. Others
      • 6.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3. Beta
      • 6.4.1.3.1. Market estimates and forecasts 2018 to 2030, (USD million)
      • 6.4.1.3.2. Blood transfusion
      • 6.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3.2.2. Iron chelation therapy
      • 6.4.1.3.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3.3. Bone marrow transplant
      • 6.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3.4. Others
      • 6.4.1.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Sickle Cell Disease
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.2. Blood transfusion
      • 6.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.3. Hydroxyurea
      • 6.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.4. Bone marrow transplant
      • 6.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.5. Others
      • 6.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. (Hb) Variants
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.3.2. Blood transfusion
      • 6.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.3.3. Hydroxyurea
      • 6.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.3.4. Bone marrow transplant
      • 6.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.3.5. Others
      • 6.4.3.6. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company heat map analysis, 2023
  • 7.4. Company Profiles
    • 7.4.1. Sangamo Therapeutics, Inc.
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Global Blood Therapeutics, Inc.
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. bluebird bio, Inc.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Emmaus Life Sciences Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Pfizer, Inc.
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Novartis AG
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Prolong Pharmaceuticals, LLC
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Bioverativ Inc.
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Celgene Corp.
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 3 U.S. hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 4 U.S. hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 5 U.S. thalassemia market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 6 U.S. hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 7 U.S. alpha thalassemia market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 8 U.S. beta thalassemia market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 9 U.S. thalassemia market, by therapy, 2018 - 2030 (USD Million)
  • Table 10 U.S. alpha thalassemia market, by therapy, 2018 - 2030 (USD Million)
  • Table 11 U.S. beta thalassemia market, by therapy, 2018 - 2030 (USD Million)
  • Table 12 U.S. sickle cell disease market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 13 U.S. sickle cell disease market, by therapy, 2018 - 2030 (USD Million)
  • Table 14 U.S. Hb Variants market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 15 U.S. hemoglobinopathies market, by region, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. hemoglobinopathies market: market outlook
  • Fig. 9 U.S. hemoglobinopathies competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 U.S. hemoglobinopathies market driver impact
  • Fig. 15 U.S. hemoglobinopathies market restraint impact
  • Fig. 16 U.S. hemoglobinopathies market strategic initiatives analysis
  • Fig. 17 U.S. hemoglobinopathies market: Type movement analysis
  • Fig. 18 U.S. hemoglobinopathies market: Type outlook and key takeaways
  • Fig. 19 Thalassemia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Sickle cell diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Other Hb variants estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. hemoglobinopathies Market: Diagnosis movement Analysis
  • Fig. 23 U.S. hemoglobinopathies market: Diagnosis outlook and key takeaways
  • Fig. 24 Thalassemia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Alpha market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Pre-implantation genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Other market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Beta market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Pre-implantation genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Other market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Sickle cell disease market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 (Hb) variants market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Blood test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Prenatal genetic test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Electrophoresis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 U.S. hemoglobinopathies Market: Therapy movement Analysis
  • Fig. 52 U.S. hemoglobinopathies market: Therapy outlook and key takeaways
  • Fig. 53 Thalassemia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Alpha market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Iron chelation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Beta market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Iron chelation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Sickle cell disease market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Hydroxyurea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 (Hb) variants market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Blood transfusion market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Hydroxyurea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Bone marrow transplant test market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 U.S. hemoglobinopathies market: regional movement analysis
  • Fig. 75 U.S. hemoglobinopathies market: regional outlook and key takeaways
  • Fig. 76 West market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)